Pharmaceutical Raw Materials
Hydrochlorothiazide is a thiazide diuretic and antihypertensive drug developed by Novartis in Switzerland in 1959. Hydrochlorothiazide is often combined with valsartan to form a compound preparation, which has a synergistic effect to increase the antihypertensive effect, enhance the antihypertensive effect, and reduce their adverse reactions.
Synonyms: HCTZ
Molecular formula: C7H8ClN3O4S2
CAS No: 58-93-5
UN NO: N/A
Application:
It is commonly used to treat high blood pressure and edema caused by fluid accumulation. Other uses include treating diabetes insipidus and renal tubular acidosis, and it may also reduce hypercalciuria, thereby reducing the risk of kidney stones. In addition, this drug is often used as a first-line drug for the treatment of high blood pressure. Hydrochlorothiazide is an oral drug that is sometimes mixed with other blood pressure-lowering drugs to make compound pills to enhance the effect of the drug.
(1) Edema diseases: including congestive heart failure, liver cirrhosis ascites, nephrotic syndrome, acute and chronic nephritis edema, early chronic renal failure, sodium and water retention caused by adrenocortical hormone and estrogen therapy.
(2) Hypertension: It can be used alone or in combination with other antihypertensive drugs, mainly for the treatment of essential hypertension.
(3) Central or nephrogenic diabetes insipidus.
(4) Nephrolithiasis: It is mainly used to prevent stones formed by calcium salts.
Specification:
USP, EP
Product process route
5-chloro-2,4-chlorosulfonylaniline is obtained by chlorosulfonation of m-chloroaniline, and then reacted with ammonia to generate 5-chloro-2,4-sulfamic acid aniline, and finally obtained by distorting formaldehyde.
Certification
USDMF, GMP.
Tianjin Chengyi International Trading Co., Ltd.
8th floor 5th Building of North America N1 Cultural and Creative Area,No. 95 South Sports Road, Xiaodian District, Taiyuan, Shanxi, China.
+86 351 828 1248 / +86 351 828 1246
Navigation